Fusion inhibitory lipopeptides engineered for prophylaxis of nipah virus in primates

Journal of Infectious Diseases

Volumn 218, Issue 2, 2018, Pages 218-227

  Mathieu, Cyrille ^a,c   Porotto, Matteo ^a   Figueira, Tiago N ^a,b   Horvat, Branka ^c   Moscona, Anne ^a  

^a NewYork Presbyterian Hospital   (United States)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

Author keywords

antivirals; lipopeptides; Nipah virus; primate model; prophylaxis

Indexed keywords

LIPOPEPTIDE; NEUTRALIZING ANTIBODY; VIRUS FUSION INHIBITOR; F PROTEIN, NIPAH VIRUS; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CHLOROCEBUS AETHIOPS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LOWER RESPIRATORY TRACT INFECTION; MALE; NIPAH VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROOF OF CONCEPT; PROTEIN ENGINEERING; SYRIAN HAMSTER; TREATMENT DURATION; ANIMAL; BRONCHOPNEUMONIA; CHEMOPROPHYLAXIS; DISEASE MODEL; HENIPAVIRUS INFECTION; HUMAN; MESOCRICETUS; NIPAH VIRUS; PHYSIOLOGY; PRIMATE DISEASE; PROCEDURES; VETERINARY MEDICINE;

ANIMALS; BRONCHOPNEUMONIA; CERCOPITHECUS AETHIOPS; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; FEMALE; HENIPAVIRUS INFECTIONS; HUMANS; LIPOPEPTIDES; MALE; MESOCRICETUS; NIPAH VIRUS; PRIMATE DISEASES; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEIN INHIBITORS;

EID: 85050869029     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy152     Document Type: Article

References (47)

1. Mathieu C, Horvat B. Henipavirus pathogenesis and antiviral approaches. Expert Rev Anti Infect Ther 2015; 13:343-54.
2. Drexler JF, Corman VM, Muller MA, et al. Bats host major mammalian paramyxoviruses. Nat Commun 2012; 3:796.
3. Marsh GA, de Jong C, Barr JA, et al. Cedar virus: a novel Henipavirus isolated from Australian bats. PLoS Pathog 2012; 8:e1002836.
4. Luby SP. The pandemic potential of Nipah virus. Antiviral Res 2013; 100:38-43.
5. Middleton D, Pallister J, Klein R, et al. Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis 2014; 20:372-9.
6. Guillaume-Vasselin V, Lemaitre L, Dhondt KP, et al. Protection from Hendra virus infection with Canarypox recombinant vaccine. NPJ Vaccines 2016; 1:16003.
7. Satterfield BA, Dawes BE, Milligan GN. Status of vaccine research and development of vaccines for Nipah virus. Vaccine 2016; 34:2971-5.
8. Mire CE, Satterfield BA, Geisbert JB, et al. Pathogenic differences between Nipah virus Bangladesh and Malaysia strains in primates: implications for antibody therapy. Sci Rep 2016; 6:30916.
9. Wang L, Harcourt BH, Yu M, et al. Molecular biology of Hendra and Nipah viruses. Microbes Infect 2001; 3:279-87.
10. Porotto M, Rockx B, Yokoyama CC, et al. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog 2010; 6:e1001168.
11. Mathieu C, Augusto MT, Niewiesk S, et al. Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides. Sci Rep 2017; 7:43610.
12. Figueira TN, Palermo LM, Veiga AS, et al. In vivo efficacy of measles virus fusion protein-derived peptides is modulated by the properties of self-assembly and membrane residence. J Virol 2017; 91: doi:10.1128/JVI.01554-16.
13. Augusto MT, Hollmann A, Porotto M, Moscona A, Santos NC. Antiviral lipopeptide-cell membrane interaction is influenced by PEG linker length. Molecules 2017; 22: doi: 10.3390/molecules22071190.
14. Escaffre O, Borisevich V, Rockx B. Pathogenesis of Hendra and Nipah virus infection in humans. J Infect Dev Ctries 2013; 7:308-11.
15. Escaffre O, Borisevich V, Carmical JR, et al. Henipavirus pathogenesis in human respiratory epithelial cells. J Virol 2013; 87:3284-94.
16. Valbuena G, Halliday H, Borisevich V, Goez Y, Rockx B. A human lung xenograft mouse model of Nipah virus infection. PLoS Pathog 2014; 10:e1004063.
17. Mathieu C, Huey D, Jurgens E, et al. Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptides. J Virol 2015; 89:1143-55.
18. Cong Y, Lentz MR, Lara A, et al. Loss in lung volume and changes in the immune response demonstrate disease progression in African green monkeys infected by small-particle aerosol and intratracheal exposure to Nipah virus. PLoS Negl Trop Dis 2017; 11:e0005532.
19. Porotto M, Yokoyama CC, Palermo LM, et al. Viral entry inhibitors targeted to the membrane site of action. J Virol 2010; 84:6760-8.
20. Ingallinella P, Bianchi E, Ladwa NA, et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A 2009; 106:5801-6.
21. Guillaume V, Contamin H, Loth P, et al. Nipah virus: vaccination and passive protection studies in a hamster model. J Virol 2004; 78:834-40.
22. Moosmann P, Rusconi S. Alpha complementation of LacZ in mammalian cells. Nucleic Acids Res 1996; 24:1171-2.
23. Porotto M, Fornabaio M, Kellogg GE, Moscona A. A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism. J Virol 2007; 81:3216-28.
24. Welsch JC, Talekar A, Mathieu C, et al. Fatal measles virus infection prevented by brain-penetrant fusion inhibitors. J Virol 2013; 87:13785-94.
25. Druelle J, Sellin CI, Waku-Kouomou D, Horvat B, Wild FT. Wild type measles virus attenuation independent of type I IFN. Virol J 2008; 5:22.
26. Dhondt KP, Mathieu C, Chalons M, et al. Type I interferon signaling protects mice from lethal henipavirus infection. J Infect Dis 2013; 207:142-51.
27. Porotto M, Doctor L, Carta P, et al. Inhibition of hendra virus fusion. J Virol 2006; 80:9837-49.
28. Porotto M, Carta P, Deng Y, et al. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. J Virol 2007; 81:10567-74.
29. Porotto M, Yokoyama CC, Palermo LM, et al. Viral entry inhibitors targeted to the membrane site of action. J Virol 2010; 84:6760-8.
30. Pessi A, Langella A, Capito E, et al. A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity. PLoS One 2012; 7:e36833.
31. Povoski SP, Davis PD, Colcher D, Martin EW Jr. Single molecular weight discrete PEG compounds: emerging roles in molecular diagnostics, imaging and therapeutics. Expert Rev Mol Diagn 2013; 13:315-9.
32. Wong KT, Grosjean I, Brisson C, et al. A golden hamster model for human acute Nipah virus infection. Am J Pathol 2003; 163:2127-37.
33. Porotto M, Rockx B, Yokoyama CC, et al. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog 2010; 6:e1001168.
34. Johnston SC, Briese T, Bell TM, et al. Detailed analysis of the African green monkey model of Nipah virus disease. PLoS One 2015; 10:e0117817.
35. Marianneau P, Guillaume V, Wong T, et al. Experimental infection of squirrel monkeys with Nipah virus. Emerg Infect Dis 2010; 16:507-10.
36. Broder CC. Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Curr Opin Virol 2012; 2:176-87.
37. Lee B. Containing the contagion: treating the virus that inspired the film. Sci Transl Med 2011; 3:105fs6.
38. Lo MK, Lowe L, Hummel KB, et al. Characterization of Nipah virus from outbreaks in Bangladesh, 2008-2010. Emerg Infect Dis 2012; 18:248-55.
39. Enserink M. Emerging infectious diseases. Nipah virus (or a cousin) strikes again. Science 2004; 303:1121.
40. Butler D. Fatal fruit bat virus sparks epidemics in Southern Asia. Nature 2004; 429:7.
41. Hsu VP, Hossain MJ, Parashar UD, et al. Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 2004; 10:2082-7.
42. Homaira N, Rahman M, Hossain MJ, et al. Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007. Epidemiol Infect 2010; 138:1630-6.
43. Marra MA, Jones SJ, Astell CR, et al. The genome sequence of the SARS-associated coronavirus. Science 2003; 300:1399-404.
44. Yuan K, Yi L, Chen J, et al. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem Biophys Res Commun 2004; 319:746-52.
45. Kahle KM, Steger HK, Root MJ. Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog 2009; 5:e1000674.
46. Welch BD, VanDemark AP, Heroux A, Hill CP, Kay MS. Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A 2007; 104:16828-33.
47. Welch BD, Francis JN, Redman JS, et al. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol 2010; 84:11235-44.